Table 3 MiRNAs evaluated in the validation phase of study

miR-378

0.004

0.002-0.006

0.008

0.004-0.037

0.0003

colorectal

carcinoma [16, 17], oral

squamous cell

carcinoma [18],

laryngeal

carcinoma [19]

SUFU, TUSC2,

TOB2, CYP2E1

miR-451

2.067

1.250-3.480

0.802

0.055-1.091

0.0001

renal cell carcinoma [1],

colorectal

carcinoma [20],

gastric cancer [20]

MMP2, MMP9,

BCL2

miR-150

0.011

0.009-0.016

0.008

0.005-0.020

0.2222

gastric cancer [21],

chronic myeloid

leukemia [22],

colorectal

carcinoma [23]

HTT, MYB,

EGFR2